{{Rsnum
|rsid=16988013
|Chromosome=X
|position=27838276
|Orientation=plus
|GMAF=0.03265
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 6.2 | 9.7 | 84.1
| ASW | 7.0 | 12.3 | 80.7
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 4.6 | 17.4 | 78.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 2.6 | 4.5 | 92.9
| TSI | 0.0 | 1.0 | 99.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs16988013
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.01, combined P value= 1.35E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470197
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs16988013
|overall_frequency_n=4
|overall_frequency_d=92
|overall_frequency=0.0434783
|n_genomes=4
|n_genomes_annotated=0
|n_haplomes=5
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}